ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "juvenile idiopathic arthritis (JIA)"

  • Abstract Number: 137 • 2020 Pediatric Rheumatology Symposium

    Measuring Decision Conflict in Parents of Children with Juvenile Idiopathic Arthritis When Making the Decision to Begin Disease Modifying Anti-Rheumatic Drugs or Biologic Agents

    Chelsea DeCoste1, Suzanne Ramsey 2, Adam Huber 3, Bianca Lang 4 and Elizabeth Stringer 2, 1The Hospital for Sick Children, Toronto, Canada, 2IWK Health Centre, Halifax, Canada, 3IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, 4Dalhousie University - Halifax, Halifax, Canada

    Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) and biologic agents are routinely used in the treatment of JIA and JIA-associated uveitis (JIA-AU). Parents are often fearful, however,…
  • Abstract Number: 060 • 2020 Pediatric Rheumatology Symposium

    Parsing Apart the Pain Experience: Exploring Treatment-Related Pain in Juvenile Idiopathic Arthritis

    Yvonne Brandelli1, Christine Chambers 2, Perri Tutelman 1, Jennifer Stinson 3, Adam Huber 4 and Jennifer Wilson 5, 1Dalhousie University, Halifax, Nova Scotia, Canada, 2Dalhousie University & IWK Health Centre, Halifax, Nova Scotia, Canada, 3University of Toronto & The Hospital for Sick Children, Toronto, Ontario, Canada, 4IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, 5Cassie and Friends, Vancouver, British Columbia, Canada

    Background/Purpose: Pain is one of the most frequently reported symptoms among children with Juvenile Idiopathic Arthritis (JIA), and in recent decades our understanding and assessment…
  • Abstract Number: 139 • 2020 Pediatric Rheumatology Symposium

    Ongoing Disease Activity in Juvenile Idiopathic Arthritis (JIA) 18 Years After Disease Onset: A Population-based Nordic Study

    Mia Glerup1, Ellen D Arnstad 2, Veronika Rypdal 3, Suvi Peltoniemi 4, Kristiina Aalto 5, Marite Rygg 6, Susan Nielsen 7, Anders Fasth 8, Lillemor Berntson 9, Ellen Nordal 3 and Troels Herlin 10, 1Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, 2Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology, and Department of Pediatrics, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway., Tromheim, Norway, 3Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Tromsø, Norway, 4Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., Helsinki, Finland, 5Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., HUS, Finland, 6Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology and Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway., Trondheim, Norway, 7Department of Pediatrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Copenhagen, Denmark, 8Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, 9Department of Womens and Childrens Health, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, 10Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Aarhus N, Denmark

    Background/Purpose: Previously, we showed that ILAR JIA categories defined at disease onset change considerably during the first 8 years of disease course. Whether achieved remission…
  • Abstract Number: 065 • 2020 Pediatric Rheumatology Symposium

    Prosthetic Temporomandibular Joint Replacement in a Cohort of Adolescent Patients with Juvenile Idiopathic Arthritis

    Jordan Jones1 and Michael Lypka 2, 1Children's Mercy Kansas City, Kansas City, 2Children's Mercy Kansas City, Kansas City, Missouri

    Background/Purpose: Temporomandibular joint (TMJ) arthritis is present in 40-96% of children with Juvenile Idiopathic Arthritis (JIA) (1). TMJ arthritis can be difficult to identify, treat,…
  • Abstract Number: 145 • 2020 Pediatric Rheumatology Symposium

    Anti-Citrullinated Protein Antibodies (ACPA) and Bony Erosions in Polyarticular JIA

    Saumya Joshi1, Yujuan Zhang 1 and Trevor Davis 2, 1Tufts Medical Center, Boston, Massachusetts, 2Norwell, Massachusetts

    Background/Purpose: Despite being a well-established biomarker for classification of aggressive bony disease in adults with RA, ACPA have not yet been described in the ILAR…
  • Abstract Number: 067 • 2020 Pediatric Rheumatology Symposium

    Response to Treatment with Intra-articular Triamcinolone Hexacetonide and Triamcinolone Acetonide in Oligo-articular Juvenile Idiopathic Arthritis

    Rana Masoud1, Wajiha Jeelani 2, Barbine Agbor Agbor 3, Teresa Hennon 2, Brian Wrotniak 4 and Rabheh Abdul Aziz 2, 1Department of Pediatrics, University at Buffalo, Oishei Children's Hospital, Buffalo, New York, 2Department of Pediatric Rheumatology, University at Buffalo, Oishei Children's Hospital, Buffalo, 3Department of Microbiology and Immunology, Jacobs School of Medicine and Biomedical Sciences, Buffalo, 4Department of Pediatrics, University at Buffalo, Oishei Children's Hospital, Buffalo, NY, USA, Buffalo

    Background/Purpose: Oligo-articular juvenile idiopathic arthritis (Oligo JIA) is the most common subtype of juvenile idiopathic arthritis. Intra-articular corticosteroid (IAC) injection is a mainstay treatment of…
  • Abstract Number: 154 • 2020 Pediatric Rheumatology Symposium

    T Helper Cell Differentiation in Polyarticular Juvenile Idiopathic Arthritis

    Anna Patrick1, Tashawna Esmond 2, David Flaherty 2, Thomas Brent Graham 2, Susan Thompson 3 and Thomas Aune 1, 1Vanderbilt University Medical Center, Nashville, Tennessee, 2Vanderbilt University Medical Center, Nashville, 3Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common autoimmune arthritis in children.  Polyarticular JIA and extended oligoarticular JIA both have genetic associations near genes…
  • Abstract Number: 003 • 2020 Pediatric Rheumatology Symposium

    Implementing Treat to Target Approach in the Care of Juvenile Idiopathic Arthritis Across a Network of Pediatric Rheumatology Centers

    Julia Harris1, Esi Morgan 2, Janalee Taylor 2, Tingting Qiu 3, Nancy Griffin 3, Anne Paul 4, C. April Bingham 5, Danielle Bullock 6, Kerry Ferraro 7, Mileka Gilbert 8, Y. Ingrid Goh 9, Olha Halyabar 10, Karla Jones 11, Melanie Kohlheim 12, Daniel J. Lovell 13, Emily Smitherman 14, Anjie Vago 7, Jennifer Weiss 15, Cagri Yildirim-Toruner 11, Angela Young 7, Michelle Batthish 16, Beth Gottlieb 17, Melissa Hazen 18, Ronald Laxer 19, Tzielan Lee 20, Melissa Mannion 14, Judyann Olson 21, Michael Shishov 22, Salma Siddique 23, Charles Spencer 24, Mary Toth 25, Sheetal Vora 26 and Jon Burnham 27, 1Children's Mercy Kansas City, Overland Park, 2Cincinnati Children's Hospital, Cincinnati, 3Cincinnati Children's Hospital Medical Center, Cincinnati, 4Cincinnati Children's Hospital Medical Centre, Cincinnati, 5Penn State Children's Hospital, Allentown, 6University of Minnesota, Minneapolis, 7Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, 8Medical University of South Carolina, Charleston, South Carolina, 9The Hospital for Sick Children, Toronto, Canada, 10Children's Hospital/Boston Medical Center, Boston, 11Nationwide Children's Hospital, Columbus, 12, 13Cincinnati, 14University of Alabama at Birmingham, Birmingham, 15Hackensack University Medical Center, Hackensack, 16McMaster University, Hamilton, Canada, 17Cohen Children's Medical Center, Lake Success, 18Boston, 19The Hospital for Sick Children and University of Toronto, Toronto, Canada, 20Stanford Children's, Palo Alto, 21Medical College of Wisconsin: Children's Wisconsin, Wauwatosa, Wisconsin, 22Phoenix Children's Hospital, Phoenix, 23Nemours/A.I.duPont Hospital for Children, Wilmington, 24Jackson, 25Nemours Foundation, Orlando, 26Atrium Health Levine Children's Hospital, Charlotte, 27Children's Hospital of Philadelphia, Philadelphia

    Background/Purpose: In 2018, an international task force published a recommended Treat to Target (T2T) approach to JIA treatment. This treatment paradigm involves setting a treatment…
  • Abstract Number: 070 • 2020 Pediatric Rheumatology Symposium

    The Importance of the Patient Global Health Assessment of Disease Activity in Polyarticular Juvenile Idiopathic Arthritis

    Rebecca Trachtman1, Daniel J. Lovell 2, Rula Issa 1, Stephanie Pan 1, Karen Wilson 1 and Karen Onel 3, 1Icahn School of Medicine at Mount Sinai, New York, 2Cincinnati, 3Hospital for Special Surgery, New York

    Background/Purpose: Polyarticular juvenile idiopathic arthritis (pJIA) is a subtype of JIA wherein more than four joints are affected with arthritis; it is characterized by unpredictable…
  • Abstract Number: 160 • 2020 Pediatric Rheumatology Symposium

    CD3 Downregulation on T-cells Is Concomitant with Arginase Upregulation on Myeloid Cells in Synovial Fluid of Patients with Juvenile Idiopathic Arthritis

    Vincent Giacalone 1, Alexandre Cammarata-Mouchtouris 1, Diego Mauricio Moncada Giraldo 1, Sreekala Shenoy 1, Lori Ponder 1, Talia Gergely 2, Patricia Vega-Fernandez 3, Cynthia Manos 4, Elaine Flanagan 1, Rabindra Tirouvanziam 1 and Sampath Prahalad5, 1emory university, atlanta, 2Emory University School of Medicine, Atlanta, 3Cincinnati Children's Hospital Medical Center, Cincinnati, 4Children's Healthcare of Atlanta, Atlanta, 5Emory + Children's Pediatric Institute, Atlanta

    Background/Purpose: Rationale: Juvenile idiopathic arthritis (JIA) is an inflammatory autoimmune disorder driven by dysfunction of the joint tissue and abnormal immune responses. As deep phenotyping…
  • Abstract Number: 004 • 2020 Pediatric Rheumatology Symposium

    Implications of Adopting the Newly Proposed Pediatric Rheumatology International Trials Organization (PRINTO) Classification Criteria for Juvenile Idiopathic Arthritis (JIA): Results from the Research in Arthritis in Canadian Children, Emphasizing Outcomes (ReACCh-Out) Cohort

    Jennifer Lee1, Simon Eng 2, Brian Feldman 3, Jaime Guzman 4, Kiem Oen 2 and Rae Yeung 3, 1University of Toronto, Toronto, Canada, 2Toronto, Canada, 3The Hospital for Sick Children, Toronto, Canada, 4University of British Columbia and BC Children's Hospital, Vancouver, Canada

    Background/Purpose: PRINTO recently proposed preliminary JIA classification criteria to revise the International League of Associations for Rheumatology (ILAR) criteria. The stated aim was to obtain…
  • Abstract Number: 074 • 2020 Pediatric Rheumatology Symposium

    Establishment of a Registry for Juvenile Idiopathic Arthritis (JIA) Patients in South Australia (SA): Focus on Patient Reported Outcome Measures (PROMs) and Experiences (PREMs)

    Ming Min 1, Catherine Gibson 2, Mark Friswell3, Tania Crotti 4 and Christina Boros 5, 1Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, North Adelaide, South Australia, Australia, 2Women's and Children's Health Network, North Adelaide, South Australia, Australia, 3Women’s and Children‘s Hospital Department of Rheumatology, Adelaide, South Australia, Australia, 4Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia, 5Women’s and Children‘s Hospital Department of Rheumatology, Adelaide, Australia

    Background/Purpose: Patient outcomes and experiences are key components in the measurement of overall health outcomes in JIA and can be measured by validated PROMs and…
  • Abstract Number: 164 • 2020 Pediatric Rheumatology Symposium

    The Juvenile Idiopathic Arthritis-Associated IL2RA and IL6R Haplotypes Contain Enhancers Whose Functions Are Altered by JIA-Associated Genetic Variants

    Kaiyu Jiang 1, Yungki Park 2, tao liu 3, Marc Sudman 4, Susan Thompson 5 and James Jarvis6, 1University at Buffalo, Buffalo, 2University at Buffalo Jacobs School of Medicine & Biomedical Sciences, Buffalo, 3Roswell Park Cancer Institute, Buffalo, 4Cincinnati Children's Hospital Medical Center, Cincinnati, 5Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, 6University at Buffalo Jacobs School of Medicine, Buffalo

    Background/Purpose: The JIA risk haplotypes, like those of other autoimmune diseases, are highly enriched for H3K4me1/H3K27ac histone marks, epigenetic features typically associated with functional enhancers.…
  • Abstract Number: L22 • 2019 ACR/ARP Annual Meeting

    Tofacitinib for the Treatment of Polyarticular Course Juvenile Idiopathic Arthritis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Withdrawal Study

    Hermine Brunner1, Olga Synoverska 2, Tracy Ting 3, Carlos Abud Mendoza 2, Alberto Spindler 2, Yulia Vyzhga 2, Katherine Marzan 3, Vladimir Keltsev 2, Irit Tirosh 2, Lisa Imundo 3, Rita Jerath 3, Daniel Kingsbury 3, Betul Sozeri 2, Sheetal Vora 3, Sampath Prahalad 3, Elena Zholobova 2, Yonatan Butbul Aviel 2, Vyacheslav Chasnyk 2, Melissa Lerman 3, Kabita Nanda 3, Heinrike Schmeling 3, Heather Tory 3, Yosef Uziel 2, Diego Oscar Viola 2, Holly Posner 4, Keith Kanik 5, Ann Wouters 4, Cheng Chang 5, Richard Zhang 4, Irina Lazariciu 6, Ming-Ann Hsu 5, Ricardo Suehiro 7, Alberto Martini 2, Daniel J. Lovell 3 and Nicolino Ruperto 8, 1PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 2PRINTO, Istituto Giannina Gaslini, Genova, Italy, 3PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 4Pfizer Inc, New York, New York, 5Pfizer Inc, Groton, Connecticut, 6IQVIA, Montreal, Quebec, Canada, 7Pfizer Inc, Collegeville, Pennsylvania, 8PRINTO, Istituto Giannina Gaslini, Genoa, Italy

    Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for JIA. Here we assess the efficacy and safety of tofacitinib in patients (pts)…
  • Abstract Number: 915 • 2019 ACR/ARP Annual Meeting

    Development and Initial Validation of the Systemic JADAS, a New Composite Disease Activity Score for Systemic Juvenile Idiopathic Arthritis

    Jessica Tibaldi1, Yasser El Miedany 2, Pryiankar Pal 3, Soamarat Vilaiyuk 4, Raju Khubchandani 5, Manuela Pardeo 6, Tapas Kumar Sabui 7, Sujata Sawhney 8, Ricardo Russo 9, Flavio Sztajnbok 10, Rolando Cimaz 11, Francesca Minoia 12, Motasem O. Alsuweiti 13, Ekaterina Alexeeva 14, Mikhail Kostik 15, Maria Cristina Maggio 16, Sulayman Al Mayouf 17, Claudia Saad 18, Giovanni Conti 19, Romina Gallizzi 20, Adele Civino 21, Masaki Shimizu 22, Enrico Felici 23, Angela Pistorio 24, Nicolino Ruperto 25, Alessandro Consolaro 26 and Angelo Ravelli 27, 1IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genoa, Italy, 2Ain Shams University, Cairo, Egypt, 3Institute of Child Health, Kolkata, India, 4Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 5Jaslok Hospital and Research Center, Mumbai, India, 6Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 7R G Kar Medical College, Kolkata, Kolkata, India, 8Department of pediatric rheumatology, Sir Ganga Ram Hospital, New Delhi, India, New Delhi, India, 9Hospital de Pediatría Garrahan, Buenos Aires, Argentina, 10Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 11University Hospital Meyer, Florence, Italy, 12Clinica De Marchi Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, 13Queen Rania Children's Hospital, Amman, Jordan, 14National Medical Research Center of Children`s Health, Moscow, Russia, 15Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, 16Università di Palermo, Dipartimento G. D'Alessandro, Palermo, Italy, 17King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, 18Hospital das Clínicas - Botucatu Medicine University, UNESP, Botucatu, Brazil, 19AOU G Martino, Messina, Italy, 20Azienda Ospedaliera Universitaria Gaetano Martino, Messina, Messina, Italy, 21Pediatric Rheumatology “Vito Fazzi” Hospital, Lecce, Lecce, Italy, 22Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa, Japan, 23SS Antonio e Biagio e Cesare Arrigo" Hospital, Alessandria, Italy, 24IRCCS Istituto Giannina Gaslini, Genova, Italy, 25Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, 26Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genova, Italy, 27IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy

    Background/Purpose: The Juvenile Arthritis Disease Activity Score (JADAS) has gained increasing popularity for the measurement of the level of disease activity in patients with juvenile…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology